This is massive news! I dont have access to the full article, but here is a quick summary
"Japanese drug major Astellas Pharma (TYO: 4503) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Astellas noted that this makes Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world.
Why is this such big news?
https://www.thepharmaletter.com/article/astellas-gets-first-approval-for-vyloy-in-japan?mc_cid=b0fef19e05
https://www.pharmaceutical-technology.com/news/astellas-secures-approval-for-gastric-cancer-antibody-in-japan/?cf-view
- Forums
- ASX - By Stock
- ALA
- Astellas gets first approval for Vyloy, in Japan
ALA
arovella therapeutics limited
Add to My Watchlist
4.76%
!
8.0¢

Astellas gets first approval for Vyloy, in Japan
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.0¢ |
Change
-0.004(4.76%) |
Mkt cap ! $95.68M |
Open | High | Low | Value | Volume |
8.3¢ | 8.3¢ | 8.0¢ | $22.44K | 274.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 197985 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.1¢ | 43665 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 197985 | 0.080 |
3 | 46825 | 0.079 |
2 | 358022 | 0.078 |
5 | 236750 | 0.077 |
4 | 177722 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.081 | 43665 | 1 |
0.082 | 73228 | 1 |
0.083 | 25787 | 1 |
0.084 | 144798 | 2 |
0.085 | 176126 | 4 |
Last trade - 16.10pm 15/09/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |
The Watchlist
FBM
FUTURE BATTERY MINERALS LIMITED
Nick Rathjen, MD & CEO
Nick Rathjen
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online